

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850



June 2025

Contact: ETC Model Team
ETC-CMMI@cms.hhs.gov

End-Stage Renal Disease Treatment Choices (ETC) Model Performance Payment Adjustment Report User Guide (Measurement Years 7-8)

Disclaimer: The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law.

Centers for Medicare & Medicaid Services End-Stage Renal Disease Treatment Choices (ETC) Model Performance Payment Adjustment (PPA) Report User Guide (Measurement Years 7-8)

Prepared for:

**Center for Medicare and Medicaid Innovation
Centers for Medicare & Medicaid Services**
7500 Security Boulevard
Baltimore, MD 21244

Prepared by:

American Institutes for Research
1400 Crystal Drive, 10th Floor
Arlington, VA 22202-3289

JUNE 2025

Reference Documents

Title
Specialty Care Models To Improve Quality of Care and Reduce Expenditures Final Rule (85 FR 61114)
End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Final Rule (86 FR 61874)
End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Final Rule (87 FR 67136)
End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Final Rule (88 FR 76344)
End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Final Rule (89 FR 89084)
Title 42/Chapter IV/Subchapter H/Part 512/Subpart C—ESRD Treatment Choices Model

Acronyms

Acronym	Explanation
AKI	Acute Kidney Injury
BY	Benchmark Year
CMS	Centers for Medicare & Medicaid Services
CPT®	Current Procedural Terminology ¹
DE	Dual Eligible
EQRS	End Stage Renal Disease Quality Reporting System
ESRD	End-Stage Renal Disease
ETC	ESRD Treatment Choices
HCC	Hierarchical Condition Category
HEI	Health Equity Incentive
HRR	Hospital Referral Region
LDT	Living Donor Transplant
LIS	Low Income Subsidy
LVT	Low Volume Threshold
MCP	Monthly Capitation Payment
MPS	Modality Performance Score
MY	Measurement Year
NPI	National Provider Identifier
PECOS	Provider Enrollment, Chain, and Ownership System
PPA	Performance Payment Adjustment
SNF	Skilled Nursing Facility
SRTR	Scientific Registry of Transplant Recipients
TIN	Taxpayer Identification Number

¹ Throughout this document, we use CPT® codes and descriptions to refer to a variety of services. We note that CPT® codes and descriptions are copyright 2020 American Medical Association. All Rights Reserved. CPT® is a registered trademark of the American Medical Association (AMA). Applicable Federal Acquisition Regulations (FAR) and Defense Federal Acquisition Regulations (DFAR) apply.

Contents

I.	Overview of ETC Model’s Performance Payment Adjustment	1
II.	PPA Calculation.....	4
III.	Benchmark Year, Measurement Year, and PPA Period.....	5
IV.	Beneficiary Attribution for PPA Calculation	7
V.	Aggregation Groups.....	9
VI.	Home Dialysis Rate	10
	Home Dialysis Rate for ESRD facilities	10
	Home Dialysis Rate for Managing Clinicians	12
VII.	Transplant Rate	13
	Transplant Rate for ESRD facilities	14
	Transplant Rate for Managing Clinicians	16
VIII.	Achievement Benchmarking and Scoring.....	18
	Achievement Benchmarks	18
	MY Rates	20
	Achievement Scores.....	20
IX.	Improvement Benchmarking and Scoring.....	21
	Improvement Benchmarks.....	21
	MY Rates	22
	Percent Improvement	22
	Health Equity Incentive	23
	Improvement Scores	24
X.	Modality Performance Score.....	25
XI.	Performance Payment Adjustment.....	26
XII.	Missing PPA	28
XIII.	Targeted Review	30
XIV.	Administrative Review.....	32
XV.	Appendix.....	33

Exhibits

Exhibit 1. PPA Calculation Flow Diagram	4
Exhibit 2a. ETC Model Schedule of BYs, MYs and PPA Periods.....	5
Exhibit 2b. ETC Model Schedule of BYs, MYs and PPA Periods (Gantt Chart)	6
Exhibit 3. Contribution of a Beneficiary to the Home Dialysis Rate Numerator by Dialysis Type	11
Exhibit 4. ETC Model Schedule of PPA Achievement Benchmarks by Measurement Year	19
Exhibit 5. Improvement Score Scale and Applicable Points	24
Exhibit 6. Facility Performance Payment Adjustment Amounts and Schedule.....	26
Exhibit 7. Clinician Performance Payment Adjustment Amounts and Schedule.....	27
Exhibit 8. Crosswalk between the PPA Report User Guide and PPA Report	33

I. Overview of ETC Model's Performance Payment Adjustment

The End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model is a mandatory payment model intended to encourage greater use of home dialysis and kidney transplants for Medicare beneficiaries with ESRD, while reducing Medicare expenditures and preserving or enhancing the quality of care furnished to beneficiaries with ESRD.² The ETC Model is based on the Specialty Care Models To Improve Quality of Care and Reduce Expenditures Final Rule (85 FR 61114), referred to herein as the Specialty Care Models final rule.³ The End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Final Rule (86 FR 61874), referred to herein as the CY 2022 ESRD PPS final rule, amended the Specialty Care Models final rule and introduced several changes to the ETC Model effective beginning in the third Measurement Year (MY3) of the Model, which started on January 1, 2022.⁴ The End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Final Rule (87 FR 67136), referred to herein as the CY 2023 ESRD PPS final rule, amended the Specialty Care Models final rule and introduced additional changes to the ETC Model effective beginning in MY5 of the Model, which started on January 1, 2023.⁵ The End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Final Rule (88 FR 76344), referred to herein as the CY 2024 ESRD PPS final rule, amended the Specialty Care Models final rule and introduced additional changes to the ETC Model effective beginning with Performance Payment Adjustment (PPA) Period 4 of the Model of the Model, which started on January 1, 2024.⁶ The End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model Final Rule (89 FR 89084), referred to herein as the CY 2025 ESRD PPS final rule, amended the Specialty Care

² <https://innovation.cms.gov/innovation-models/esrd-treatment-choices-model>

³ <https://www.federalregister.gov/documents/2020/09/29/2020-20907/medicare-program-specialty-care-models-to-improve-quality-of-care-and-reduce-expenditures>

⁴ <https://www.federalregister.gov/documents/2021/11/08/2021-23907/medicare-program-end-stage-renal-disease-prospective-payment-system-payment-for-renal-dialysis>

⁵ <https://www.federalregister.gov/documents/2022/11/07/2022-23778/medicare-program-end-stage-renal-disease-prospective-payment-system-payment-for-renal-dialysis>

⁶ <https://www.federalregister.gov/documents/2023/11/06/2023-23915/medicare-program-end-stage-renal-disease-prospective-payment-system-payment-for-renal-dialysis>

Models final rule and introduced additional changes to the ETC Model effective beginning in MY9 of the Model, which started on January 1, 2025.⁷ The Specialty Care Models final rule and relevant amendments to the ETC Model (in the CY 2022 ESRD PPS final rule, the CY 2023 ESRD PPS final rule, the CY 2024 ESRD PPS final rule, and the CY 2025 ESRD PPS final rule) are codified in Title 42 of the Code of Federal Regulations at part 512 (42 CFR § 512) - ESRD Treatment Choices Model.⁸

The Centers for Medicare & Medicaid Services (CMS) randomly selects Hospital Referral Regions (HRRs) for inclusion in the ETC Model. All eligible ESRD facilities and clinicians who manage dialysis patients (Managing Clinicians) located in selected HRRs (Selected Geographic Areas) are required to participate in the ETC Model.

Following each MY, CMS separately calculates the home dialysis rate and the transplant rate at the ESRD facility and Managing Clinician aggregation group levels using the methodologies described in the Specialty Care Models final rule, the CY 2022 ESRD PPS final rule, the CY 2023 ESRD PPS final rule, the CY 2024 ESRD PPS final rule, and the CY 2025 ESRD PPS final rule.

CMS compares the aggregation group's home dialysis rate and transplant rate to their applicable achievement and improvement benchmarks and assigns a Modality Performance Score (MPS). CMS will determine the magnitude of the aggregation group's PPA based on the MPS according to the schedule in the Specialty Care Models final rule. The PPA applies to all aggregation groups located within Selected Geographic Areas in both the Benchmark Year (BY) and the corresponding MY with at least 11 attributed beneficiary years or 132 attributed beneficiary months during the MY.

As described in § 512.390(a) (Notification) of the Specialty Care Models final rule, CMS will notify ETC Participants of their performance benchmarks and rates, MPS, and PPA in advance of a PPA Period. Each ETC Participant's performance is summarized in a customized PPA Report which will be provided to the Participant no later than one month before the start of the applicable PPA Period. This guide accompanies the ETC Participant PPA Report and describes the methods that CMS uses to calculate the achievement and improvement benchmarks, MY home dialysis rate, and transplant rate, and how these performances translate into aggregation group level MPS and PPA.

This user guide is for MY7 and MY8 and corresponding ETC Participant PPA reports.⁹ A crosswalk between the sections of the user guide and the tabs of the PPA report is included in the Appendix. ETC Participants without any attributed beneficiaries during an MY or BY will not

⁷ <https://www.federalregister.gov/documents/2024/11/12/2024-25486/medicare-program-end-stage-renal-disease-prospective-payment-system-payment-for-renal-dialysis>

⁸ <https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-H/part-512/subpart-C>


⁹ CMS will update the guide when there are changes in the methodology or implementation of the ESRD ETC Model in future MYs.

receive a PPA for that MY and will be notified through a PPA Report containing only a ReadMe section that displays the associated PPA Period, MY, and BY.

The remainder of this guide is organized as follows: Section II displays the PPA calculation process using a flow diagram. Section III provides the BYs, MYs, and PPA periods. Beneficiary attribution and aggregation groups are described in Sections IV and V. Sections VI and VII describe the calculation of the home dialysis rate and transplant rate. Achievement benchmarking and scoring process is described in Section VIII, and improvement benchmarking and scoring process is described in Section IX. Sections X and XI explain how achievement and improvement scoring translate into MPS and PPA. Section XII provides the reasons why MPS and PPA might be missing for some ETC Participants. Section XIII describes the targeted review process. Section XIV describes the administrative review process. The Appendix provides the user guide-ETC Participant PPA report crosswalk.

II. PPA Calculation

Exhibit 1. PPA Calculation Flow Diagram




III. Benchmark Year, Measurement Year, and PPA Period

As described in § 512.310 (Definitions) of the Specialty Care Models final rule, BY means the 12-month period that begins 18 months prior to the start of a given MY from which data are used to construct benchmarks against which to score an ETC Participant's aggregation group's achievement and improvement on the home dialysis rate and transplant rate for the purpose of calculating the ETC Participant's MPS. As described in § 512.355(a) (Measurement Years) of the Specialty Care Models final rule, CMS assesses ETC Participant's aggregation group's performance on the home dialysis rate and the transplant rate during each of the MYs. The first MY begins on January 1, 2021, and the final MY ends on June 30, 2026. As described in § 512.355(b) (Performance Payment Adjustment Period) of the Specialty Care Models final rule, CMS adjusts certain payments to ETC Participants by the PPA during each of the PPA Periods, each of which corresponds to an MY. The first PPA Period begins on July 1, 2022, and the final PPA Period ends on June 30, 2027. Exhibit 2a and 2b display the BY, MY, and PPA Period schedule, as described in § 512.355(c) (Measurement Years and Performance Payment Adjustment Periods) of the Specialty Care Models final rule.

Exhibit 2a. ETC Model Schedule of BYs, MYs and PPA Periods

BY	MY	PPA Period
BY 1 - 7/1/2019 through 6/30/2020	MY 1 - 1/1/2021 through 12/31/2021	PPA Period 1 - 7/1/2022 through 12/31/2022
BY 2 - 1/1/2020 through 12/31/2020	MY 2 - 7/1/2021 through 6/30/2022	PPA Period 2 - 1/1/2023 through 6/30/2023
BY 3 - 7/1/2020 through 6/30/2021	MY 3 - 1/1/2022 through 12/31/2022	PPA Period 3 - 7/1/2023 through 12/31/2023
BY 4 - 1/1/2021 through 12/31/2021	MY 4 - 7/1/2022 through 6/30/2023	PPA Period 4 - 1/1/2024 through 6/30/2024
BY 5 - 7/1/2021 through 6/30/2022	MY 5 - 1/1/2023 through 12/31/2023	PPA Period 5 - 7/1/2024 through 12/31/2024
BY 6 - 1/1/2022 through 12/31/2022	MY 6 - 7/1/2023 through 6/30/2024	PPA Period 6 - 1/1/2025 through 6/30/2025
BY 7 - 7/1/2022 through 6/30/2023	MY 7 - 1/1/2024 through 12/31/2024	PPA Period 7 - 7/1/2025 through 12/31/2025
BY 8 - 1/1/2023 through 12/31/2023	MY 8 - 7/1/2024 through 6/30/2025	PPA Period 8 - 1/1/2026 through 6/30/2026
BY 9 - 7/1/2023 through 6/30/2024	MY 9 - 1/1/2025 through 12/31/2025	PPA Period 9 - 7/1/2026 through 12/31/2026
BY 10 - 1/1/2024 through 12/31/2024	MY 10 - 7/1/2025 through 6/30/2026	PPA Period 10 - 1/1/2027 through 6/30/2027

Exhibit 2b. ETC Model Schedule of BYs, MYs and PPA Periods (Gantt Chart)



IV. Beneficiary Attribution for PPA Calculation

An ETC Participant's (ESRD facility or Managing Clinician) PPA is calculated based on the beneficiaries attributed to the Participant during the MY.¹⁰ As specified in § 512.360 (Beneficiary Population and Attribution) of the Specialty Care Models final rule, CMS attributes ESRD beneficiaries to an ETC Participant for each month during an MY based on the ESRD Beneficiary's receipt of ESRD-related services (non-AKI [acute kidney injury] 72X claims for ESRD facilities and Monthly Capitation Payment [MCP] claims for Managing Clinicians) during the month. Beneficiaries who meet one or more of the exclusion criteria listed in § 512.360(b) (Exclusions from Attribution) of the Specialty Care Models final rule during a month is not attributed in the given month. CMS does not attribute an ESRD Beneficiary or Pre-emptive Living Donor Transplant (LDT) Beneficiary to an ETC Participant for a month if, at any point during the month, the beneficiary —

- Is not enrolled in Medicare Part B;
- Is enrolled in Medicare Advantage, a cost plan, or other Medicare managed care plan;
- Does not reside in the United States;
- Is younger than 18 years of age before the first day of the month of the claim service date;
- Has elected hospice;
- Is receiving dialysis only for any AKI;
- Has a diagnosis of dementia at any point during the month of the claim service date or the preceding 12 months, as identified using the most recent dementia-related criteria at the time of beneficiary attribution, using the CMS-HCC (Hierarchical Condition Category) Risk Adjustment Model ICD-10-CM Mappings; or
- Is residing in or receiving dialysis in a skilled nursing facility (SNF) or nursing facility.

For MY3 through MY10, CMS attributes Pre-emptive LDT Beneficiaries to Managing Clinicians for one or more months during an MY based on the Beneficiary's receipt of services as specified in § 512.360(c)(2)(iii) (Managing Clinician Beneficiary Attribution) of the Specialty Care Models final rule as amended by the CY 2022 ESRD PPS final rule. A Pre-emptive LDT Beneficiary who is not excluded based on the criteria in § 512.360(b) (Exclusions from Attribution) of the Specialty Care Models final rule and listed above is attributed to the Managing Clinician who submitted

¹⁰ Beneficiaries attributed to Participants during BYs also affect the PPA process through improvement benchmarking and scoring.

the most claims for services furnished to the beneficiary in the 365 days preceding the date in which the beneficiary received the transplant.¹¹

- (A) If no Managing Clinician has had the most claims for a given Pre-emptive LDT Beneficiary such that multiple Managing Clinicians each had the same number of claims for that beneficiary in the 365 days preceding the date of the transplant, the Pre-emptive LDT Beneficiary is attributed to the Managing Clinician associated with the latest claim service date at the claim line through date during the 365 days preceding the date of the transplant.
- (B) If no Managing Clinician had the most claims for a given Pre-emptive LDT Beneficiary such that multiple Managing Clinicians each had the same number of claims for that beneficiary in the 365 days preceding the date of the transplant, and more than one of those Managing Clinicians had the latest claim service date at the claim line through date during the 365 days preceding the date of the transplant, the Pre-emptive LDT Beneficiary is randomly attributed to one of these Managing Clinicians.
- (C) The Pre-emptive LDT Beneficiary is considered eligible for attribution under § 512.360 (c)(2)(iii) of the Specialty Care Models final rule if the Pre-emptive LDT Beneficiary has at least one eligible month during the 12-month period that includes the month of the transplant and the 11 months prior to the month of the transplant. An eligible month refers to a month during which the Pre-emptive LDT Beneficiary does not meet exclusion criteria in § 512.360(b) (Exclusions from Attribution) of the Specialty Care Models final rule and listed above.

As specified in § 512.360 (Beneficiary Population and Attribution) of the Specialty Care Models final rule, CMS attributes an ESRD Beneficiary to no more than one ESRD facility and no more than one Managing Clinician for a given month during a given MY. CMS attributes a Pre-emptive LDT Beneficiary to no more than one Managing Clinician for a given MY.

CMS makes available to each ETC Participant the list of Beneficiaries and beneficiary months attributed to them for the MY through a Beneficiary-level Attribution Report. This report is available for a PPA Period no later than one month before the start of the applicable PPA Period. The report includes identifiable details of each attributed Beneficiary and other Beneficiary data (e.g., whether the Beneficiary received home dialysis in a month).

¹¹ For MY3 through MY10, the CY 2022 ESRD PPS final rule extended the claim plurality check period from the start of the MY and the month of the transplant to 365 days preceding the date of the transplant. The CY 2022 ESRD PPS final rule also extended the period during which a beneficiary needs to have at least one eligible month in order to be attributed from the start of the MY and the month of the transplant to the month of the transplant and 11 months preceding the month of the transplant.

V. Aggregation Groups

As described in § 512.365(e)(1) (Aggregation of ESRD Facilities) of the Specialty Care Models final rule, an ESRD facility's home dialysis rate and transplant rate are aggregated to the ESRD facility's aggregation group for performance assessment. The aggregation group for a Subsidiary ESRD facility includes all ESRD facilities owned in whole or in part by the same legal entity located in the HRR in which the ESRD facility is located. An ESRD facility that is not a Subsidiary ESRD facility is not included in an aggregation group.

Subsidiary ESRD facilities within an aggregation group are primarily identified using the Chain Taxpayer Identification Number (TIN) and the Chain Legal Name documented in CMS Medicare Provider Enrollment, Chain, and Ownership System (PECOS). CMS also uses data from End Stage Renal Disease Quality Reporting System (EQRS) and other CMS data sources to correct typographical errors and resolve ambiguities in PECOS records. CMS sends an aggregation group notification letter regarding a facility's status as a Subsidiary ESRD facility at the beginning of each MY. This letter includes a list of the facility and, if applicable, other facilities in the facility's aggregation group during the associated BY. If the list of facilities includes only the facility, then the facility is not part of an aggregation group because CMS has determined that it is either not a Subsidiary ESRD facility or that there is no other ESRD facility owned in whole or in part by the same company within the same HRR.

As described in § 512.365(e)(2) (Aggregation for Managing Clinicians) of the Specialty Care Models final rule, the aggregation group for Managing Clinicians in a group practice, as identified by practice TIN, includes all Managing Clinicians within the HRR in which the group practice is located. Managing Clinicians who are solo practitioners, as identified by individual National Provider Identifier (NPI) and TIN, are not aggregated. The identification of aggregation groups for Managing Clinicians is based only on NPI and TIN and does not require additional data sources or processes as in the case of ESRD facilities. Therefore, CMS does not send aggregation letters to Managing Clinicians at the beginning of each MY.

Aggregation groups will be reassessed after the end of the MY and may change over time for various reasons (e.g., due to facilities that open, close, or change affiliation). The updated list produced after the end of the MY will be used for calculating the Participant's performance rates, MPS and PPA. The **"4.AG_Participant_List"** tab of the PPA Report provides the final list of ETC Participants at the end of the MY in the ETC Participant's aggregation group.

VI. Home Dialysis Rate

As described in § 512.365(b), Part 512—Radiation Oncology Model and End Stage Renal Disease Treatment Choices Model, of the CY 2022 ESRD PPS final rule, which amended § 512.365(b) (Home Dialysis Rate) of the Specialty Care Models final rule, CMS calculates the home dialysis rate for ESRD facilities and Managing Clinicians as follows.¹²

Home Dialysis Rate =

$$\frac{\text{Number of attributed ESRD Beneficiary months in MY using home dialysis} + (0.5 * \text{Number of attributed ESRD Beneficiary months in MY using self or nocturnal dialysis with no home dialysis})}{\text{Total number of attributed ESRD Beneficiary months in MY}}$$

Home Dialysis Rate for ESRD facilities

The denominator is the total dialysis treatment beneficiary years for attributed ESRD Beneficiaries during the MY. Dialysis treatment beneficiary years included in the denominator are composed of those months during which an attributed ESRD Beneficiary received maintenance dialysis at home or in an ESRD facility, such that one beneficiary year is composed of 12 beneficiary months. Months during which attributed ESRD Beneficiaries received maintenance dialysis are identified by claims with Type of Bill 072X.

The numerator is the total number of home dialysis treatment beneficiary years plus one half the total number of beneficiary years with either in center self-dialysis or nocturnal in center dialysis treatment without simultaneous home dialysis for attributed ESRD Beneficiaries during the MY.

Home dialysis treatment beneficiary years included in the numerator are composed of those months during which attributed ESRD Beneficiaries received maintenance dialysis at home, such that one beneficiary year is comprised of 12 beneficiary months. Months in which an attributed ESRD Beneficiary received maintenance dialysis at home are identified by claims with Type of Bill 072X and condition codes 74 or 76.

In center self-dialysis treatment beneficiary years included in the numerator are composed of those months during which attributed ESRD Beneficiaries received self-dialysis in center, such

¹² CY 2022 ESRD PPS final rule newly included nocturnal in center dialysis in the numerator of the home dialysis rate for MY3 through MY10.

that one beneficiary year is comprised of 12 beneficiary months. Months in which an attributed ESRD Beneficiary received in center self-dialysis are identified by claims with Type of Bill 072X and condition code 72. If a patient receives both home dialysis and in center self-dialysis in a month, that month will be included as home dialysis in the numerator of the home dialysis rate.

Nocturnal in center dialysis beneficiary years included in the numerator are composed of those months during which attributed ESRD Beneficiaries received nocturnal in center dialysis, such that one beneficiary year is comprised of 12 beneficiary months. Months in which an attributed ESRD Beneficiary received nocturnal in center dialysis are identified by claims with Type of Bill 072X and modifier UJ.

Information used to calculate the ESRD facility home dialysis rate includes Medicare claims data and Medicare administrative data.

The home dialysis rate for an ESRD facility is calculated at its aggregation group level, as described in Section V. For calculating the aggregation group's home dialysis rate, the beneficiary months of each ESRD facility in the aggregation group are summed up to the aggregation group level. This aggregation is done for both the numerator and denominator beneficiary months.

Exhibit 3 illustrates the home dialysis rate numerator contributions of an attributed ESRD beneficiary who had all three types of dialysis in a beneficiary year. If an ESRD beneficiary uses home dialysis in a month, as identified in an ESRD facility's attribution data, the entire ESRD beneficiary month will be counted in the numerator (numerator contribution = 1), regardless of whether in center self-dialysis or nocturnal in center dialysis was used in the same ESRD beneficiary month. If an ESRD beneficiary uses in center self-dialysis and/or nocturnal in center dialysis but not home dialysis in a month, as identified in the ESRD facility's attribution data, only half of the ESRD beneficiary month will be counted in the numerator (numerator contribution = 0.5).

Exhibit 3. Contribution of a Beneficiary to the Home Dialysis Rate Numerator by Dialysis Type

Contribution to the Home Dialysis Rate Numerator (in ESRD Beneficiary Months)	ESRD Beneficiary Month has Home Dialysis	ESRD Beneficiary Month has In-center Self Dialysis	ESRD Beneficiary Month has Nocturnal In-center Dialysis
1	YES	YES	YES
1	YES	YES	NO
1	YES	NO	YES

Contribution to the Home Dialysis Rate Numerator (in ESRD Beneficiary Months)	ESRD Beneficiary Month has Home Dialysis	ESRD Beneficiary Month has In-center Self Dialysis	ESRD Beneficiary Month has Nocturnal In-center Dialysis
1	YES	NO	NO
0.5	NO	YES	YES
0.5	NO	YES	NO
0.5	NO	NO	YES
0	NO	NO	NO

Home Dialysis Rate for Managing Clinicians

The denominator is the total dialysis treatment beneficiary years for attributed ESRD Beneficiaries during the MY. Dialysis treatment beneficiary years included in the denominator are composed of those months during which an attributed ESRD Beneficiary received maintenance dialysis at home or in an ESRD facility, such that one beneficiary year is comprised of 12 beneficiary months. Months during which an attributed ESRD Beneficiary received maintenance dialysis are identified by claims with Current Procedural Terminology® (CPT®) codes 90957, 90958, 90959, 90960, 90961, 90962, 90965, or 90966.

The numerator is the total number of home dialysis treatment beneficiary years, plus one half the total number of beneficiary years with either in center self-dialysis or nocturnal in center treatment without simultaneous home dialysis for attributed ESRD Beneficiaries during the MY.

Home dialysis treatment beneficiary years included in the numerator are composed of those months during which an attributed ESRD Beneficiary received maintenance dialysis at home, such that one beneficiary year is comprised of 12 beneficiary months. Months in which an attributed ESRD Beneficiary received maintenance dialysis at home are identified by claims with CPT® codes 90965 or 90966.

In center self-dialysis treatment beneficiary years included in the numerator are composed of those months during which an attributed ESRD Beneficiary received self-dialysis in center, such that one beneficiary year is comprised of 12 beneficiary months. Months in which an attributed ESRD Beneficiary received in center self-dialysis are identified by claims with Type of Bill 072X and condition code 72.

Nocturnal in center dialysis beneficiary years included in the numerator are composed of those months during which attributed ESRD Beneficiaries received nocturnal in center dialysis, such that one beneficiary year is comprised of 12 beneficiary months. Months in which an attributed

ESRD Beneficiary received nocturnal in center dialysis are identified by claims with Type of Bill 072X and modifier UJ.

Information used to calculate the Managing Clinician home dialysis rate includes Medicare claims data and Medicare administrative data.

The home dialysis rate for a Managing Clinician is calculated at its aggregation group level, as described in Section V. For calculating the aggregation group's home dialysis rate, the beneficiary months of each Managing Clinician in the aggregation group are summed up to the aggregation group level. This aggregation is done for both the numerator and denominator beneficiary months. Exhibit 3 and the associated example of home dialysis rate numerator calculation also apply to Managing Clinicians.

VII. Transplant Rate

As described in § 512.365(c) (Transplant Rate) of the Specialty Care Models final rule, CMS calculates the transplant rate for ESRD facilities and Managing Clinicians as follows.

$$\text{Transplant Rate} = \frac{\text{Risk Adjusted Transplant Waitlist Rate in MY}}{\text{Transplant Waitlist Rate in MY}} + \frac{\text{Living Donor Transplant Rate in MY}}{\text{Transplant Rate in MY}}$$

$$\frac{\text{Risk Adjusted Transplant Waitlist Rate in MY}}{\text{Transplant Waitlist Rate in MY}} = \frac{\frac{\text{Observed Transplant Waitlist Rate in MY}}{\text{Expected Transplant Waitlist Rate in MY}} * \text{Reference Transplant Waitlist Rate in BY}}{\text{Transplant Waitlist Rate in MY}}$$

$$\frac{\text{Living Donor Transplant Rate in MY}}{\text{Transplant Rate in MY}} = \frac{\frac{\text{Number of Living Donor Transplant Beneficiary months for ESRD Beneficiaries in MY}}{\text{Total Number of attributed ESRD Beneficiary months in MY}}}{\text{Transplant Rate in MY}}$$

As described in § 512.365(d) (Risk Adjustment) of the Specialty Care Models final rule, CMS risk adjusts the transplant waitlist rate based on beneficiary age with separate risk coefficients for the following age categories of beneficiaries, with age computed on the last day of each month of the MY: 18 to 55, 56 to 70, and 71 to 74. The transplant waitlist rate risk-adjustment is described below in “Risk Adjustment of transplant waitlist rate for ESRD facilities.”

Transplant Rate for ESRD facilities

The transplant rate for ESRD facilities is the sum of the transplant waitlist rate for ESRD facilities and the LDT rate for ESRD facilities, as described below.

Transplant waitlist rate for ESRD facilities

The denominator is the total dialysis treatment beneficiary years for attributed ESRD Beneficiaries during the MY. Dialysis treatment beneficiary years included in the denominator are composed of those months during which an attributed ESRD beneficiary received maintenance dialysis at home or in an ESRD facility, such that one beneficiary year is comprised of 12 beneficiary months. Months during which an attributed ESRD Beneficiary received maintenance dialysis are identified by claims with Type of Bill 072X, excluding claims for beneficiaries who were 75 years of age or older at any point during the month, or had a vital solid organ cancer diagnosis and were receiving treatment with chemotherapy or radiation for vital solid organ cancer during the MY.¹³

An attributed ESRD Beneficiary is considered to have a diagnosis of vital solid organ cancer in an MY if the beneficiary had any of the diagnosis codes listed in § 512.365(c)(1)(i)(A)(1) of the CY 2022 ESRD PPS final rule on any claim during the MY or the 6 months prior to the start of the MY. An attributed ESRD Beneficiary is considered to have received treatment with chemotherapy or radiation for vital solid organ cancer during the MY if the beneficiary had a claim with any of the procedure codes listed in § 512.365(c)(1)(i)(A)(2) of the CY 2022 ESRD PPS final rule on any claim during the MY or the 6 months prior to the start of the MY.

The numerator is the total number of attributed beneficiary years for which attributed ESRD Beneficiaries were on the kidney transplant waitlist. Months during which an attributed ESRD Beneficiary was on the kidney transplant waitlist are identified using data from the Scientific Registry of Transplant Recipients (SRTR) database.

Risk Adjustment of transplant waitlist rate for ESRD Facilities

The transplant waitlist rate is calculated as a risk adjusted rate to account for variation in transplant waitlisting related to age and to ensure that the performance of ESRD facility aggregation groups that differ in terms of the age distributions of their attributed ESRD Beneficiaries can be accurately compared. As described in § 512.365(d) (Risk Adjustment) of the Specialty Care Models final rule, CMS risk adjusts the transplant waitlist rate based on beneficiary age with separate risk coefficients for the following age categories of beneficiaries, with age computed on the last day of each month of the MY: 18 to 55, 56 to 70, and 71 to 74. CMS estimates the risk coefficients based on the

¹³ CY 2022 ESRD PPS final rule newly included the vital solid organ cancer diagnosis and treatment related exclusion for MY3 through MY10.

- ETC non-participant experience during the BY for achievement scoring, and
- ETC participant experience during the BY for improvement scoring.

Due to differences in reference population for the risk-adjusted transplant waitlist rate in MY, the transplant rate in MY for achievement scoring may be slightly different from the transplant rate in MY for improvement scoring.

CMS uses these risk coefficients to calculate a predicted probability of attributed ESRD beneficiary months spent on a transplant waitlist during the MY.

The risk-adjusted transplant waitlist rate in the MY is calculated as follows:

$$\text{Risk Adjusted Transplant Waitlist Rate in MY} = \frac{\text{Observed Transplant Waitlist Rate in MY}}{\text{Expected Transplant Waitlist Rate in MY}} * \frac{\text{Reference Transplant Waitlist Rate in BY}}{\text{Waitlist Rate in MY}}$$

The observed rate varies by aggregation group. It is the percent of ESRD Beneficiary months attributed to an ESRD facility aggregation group that were represented on a transplant waitlist during the MY.

The expected rate also varies by aggregation group. It is the predicted percent of ESRD Beneficiary months during which an ESRD Beneficiary attributed to an ESRD facility aggregation group was represented on a transplant waitlist during the MY. The prediction is based on the expected experience in the BY of the relevant reference population if it were to treat ESRD Beneficiaries with the same age-mix as that of the ESRD facility aggregation group.

The reference population varies for achievement scoring and improvement scoring. The reference rate is the observed rate for all ESRD beneficiaries attributed to

- all non-participating ESRD facility aggregation groups during the BY for achievement scoring, and
- all participating ESRD facility aggregation groups during the BY for improvement scoring.

Living donor transplant rate for ESRD facilities

The denominator is the total dialysis treatment beneficiary years for attributed ESRD Beneficiaries during the MY. Dialysis treatment beneficiary years included in the denominator are composed of those months during which an attributed ESRD Beneficiary received maintenance dialysis at home or in an ESRD facility, such that one beneficiary year is comprised of 12 beneficiary months. Months during which an attributed ESRD Beneficiary received maintenance dialysis are identified by claims with Type of Bill 072X, excluding claims for beneficiaries who were 75 years of age or older at any point during the month, or had a vital

solid organ cancer diagnosis and were receiving treatment with chemotherapy or radiation for vital solid organ cancer during the MY.¹⁴ Months in which an attributed ESRD Beneficiary had a diagnosis of vital solid organ cancer are identified as described in § 512.365(c)(1)(i)(A)(1) of the CY 2022 ESRD PPS final rule. Months in which an attributed ESRD Beneficiary received treatment with chemotherapy or radiation for vital solid organ cancer are identified as described in § 512.365(c)(1)(i)(A)(2) of the CY 2022 ESRD PPS final rule.

The numerator is the total number of attributed beneficiary years for LDT Beneficiaries during the MY. Beneficiary years for LDT Beneficiaries included in the numerator are composed of those months between the beginning of the MY up to and including the month of the transplant for LDT Beneficiaries attributed to an ESRD facility during the month of the transplant. LDT Beneficiaries are identified using information about LDTs from the SRTR Database and Medicare claims data.

Transplant Rate for Managing Clinicians

The transplant rate for Managing Clinicians is the sum of the transplant waitlist rate for Managing Clinicians and the LDT rate for Managing Clinicians, as described below. For Managing Clinicians, the Pre-emptive LDT beneficiary years are included in the LDT rate.

Transplant waitlist rate for Managing Clinicians

The denominator is the total dialysis treatment beneficiary years for attributed ESRD Beneficiaries during the MY. Dialysis treatment beneficiary years included in the denominator are composed of those months during which an attributed ESRD Beneficiary received maintenance dialysis at home or in an ESRD facility, such that one beneficiary year is comprised of 12 beneficiary months. Months during which an attributed ESRD Beneficiary received maintenance dialysis are identified by claims with CPT® codes 90957, 90958, 90959, 90960, 90961, 90962, 90965, or 90966, excluding claims for beneficiaries who were 75 years of age or older at any point during the month, or had a vital solid organ cancer diagnosis and were receiving treatment with chemotherapy or radiation for vital solid organ cancer during the MY. Months in which an attributed ESRD Beneficiary had a diagnosis of vital solid organ cancer are identified as described in § 512.365(c)(1)(i)(A)(1) of the CY 2022 ESRD PPS final rule. Months in which an attributed ESRD Beneficiary received treatment with chemotherapy or radiation for vital solid organ cancer are identified as described in § 512.365(c)(1)(i)(A)(2) of the CY 2022 ESRD PPS final rule.

The numerator is the total number of attributed beneficiary years for which attributed ESRD Beneficiaries were on the kidney transplant waitlist. Months during which an attributed ESRD

¹⁴ CY 2022 ESRD PPS final rule newly included the vital solid organ cancer diagnosis and treatment related exclusion for MY3 through MY10.

Beneficiary was on the kidney transplant waitlist are identified using data from the SRTR database.

Risk Adjustment of transplant waitlist rate for Managing Clinicians

CMS uses the same process to risk adjust the transplant waitlist rate for ESRD facilities and Managing Clinicians. This process is described earlier in “Risk Adjustment of transplant waitlist rate for ESRD Facilities.”

Living donor transplant rate for Managing Clinicians

The denominator is the sum of the total dialysis treatment beneficiary years for attributed ESRD Beneficiaries during the MY and the total Pre-emptive LDT beneficiary years for attributed beneficiaries during the MY.

Dialysis treatment beneficiary years included in the denominator are composed of those months during which an attributed ESRD Beneficiary received maintenance dialysis at home or in an ESRD facility, such that one beneficiary year is comprised of 12 beneficiary months. Months during which an attributed ESRD Beneficiary received maintenance dialysis are identified by claims with CPT® codes 90957, 90958, 90959, 90960, 90961, 90962, 90965, or 90966, excluding claims for beneficiaries who were 75 years of age or older at any point during the month, or had a vital solid organ cancer diagnosis and were receiving treatment with chemotherapy or radiation for vital solid organ cancer during the MY.¹⁵ Months in which an attributed ESRD Beneficiary had a vital solid organ cancer diagnosis are identified as described in § 512.365(c)(1)(i)(A)(1) of the CY 2022 ESRD PPS final rule. Months in which an attributed ESRD Beneficiary received treatment with chemotherapy or radiation for vital solid organ cancer are identified as described in § 512.365(c)(1)(i)(A)(2) of the CY 2022 ESRD PPS final rule.

Pre-emptive LDT beneficiary years included in the denominator are composed of those months during which a Pre-emptive LDT Beneficiary is attributed to a Managing Clinician, from the beginning of the MY up to and including the month of the LDT, excluding beneficiaries who had a vital solid organ cancer diagnosis and were receiving treatment with chemotherapy or radiation for vital solid organ cancer during the MY. Months in which an attributed ESRD Beneficiary had a vital solid organ cancer diagnosis are identified as described in § 512.365(c)(1)(i)(A)(1) of the CY 2022 ESRD PPS final rule. Months in which an attributed ESRD Beneficiary received treatment with chemotherapy or radiation for vital solid organ cancer are identified as described in § 512.365(c)(1)(i)(A)(2) of the CY 2022 ESRD PPS final rule. Pre-emptive LDT Beneficiaries are identified using information about LDTs from the SRTR Database and Medicare claims data.

¹⁵ CY 2022 ESRD PPS final rule newly included the vital solid organ cancer diagnosis and treatment related exclusion for MY3 through MY10.

The numerator is the sum of the total number of attributed beneficiary years for LDT Beneficiaries during the MY and the total number of attributed beneficiary years for Pre-emptive LDT Beneficiaries during the MY.

Beneficiary years for LDT Beneficiaries included in the numerator are composed of those months during which an LDT Beneficiary is attributed to a Managing Clinician, from the beginning of the MY up to and including the month of the transplant. LDT Beneficiaries are identified using information about LDTs from the SRTR Database and Medicare claims data.

Beneficiary years for Pre-emptive LDT Beneficiaries included in the numerator are composed of those months during which a Pre-emptive LDT Beneficiary is attributed to a Managing Clinician, from the beginning of the MY up to and including the month of the transplant. Pre-emptive LDT Beneficiaries are identified using information about LDTs from the SRTR Database and Medicare claims data.

VIII. Achievement Benchmarking and Scoring

As described in § 512.370(b) (Achievement Scoring) of the Specialty Care Models final rule, CMS assesses ETC Participant performance at the aggregation group level on the home dialysis rate and transplant rate against benchmarks constructed based on the home dialysis rate and transplant rate among aggregation groups of ESRD facilities and Managing Clinicians located in Comparison Geographic Areas, i.e., HRRs that were not selected to participate in the ETC Model, during the BY.

Achievement Benchmarks

Achievement benchmarks for the ETC Model are based on historical home dialysis rate and transplant rate of non-participating ESRD facilities and Managing Clinicians who provide care in Comparison Geographic Areas. Achievement benchmarks are based on a 12-month time period, referred to as the BY, that begins 18 months before the start of the MY and ends 6 months prior to the MY.

Achievement benchmarks are calculated as described in § 512.370(b)(1) of the CY 2022 ESRD PPS final rule and displayed in Exhibit 4 below and, for MY3 through MY10, are stratified as described in § 512.370(b)(2) of the CY 2022 ESRD PPS final rule. As shown in Exhibit 4, CY 2022 ESRD PPS final rule increased the achievement benchmarks above the Comparison Geographic Area rates during the BY by 10 percent every two MYs, beginning MY3.

Exhibit 4. ETC Model Schedule of PPA Achievement Benchmarks by Measurement Year

MY1 and MY2	MY3 and MY4	MY5 and MY6	MY7 and MY8	MY9 and MY10	Points
90th + percentile of rates for Comparison Geographic Areas during the BY	1.1 * (90th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.2 * (90th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.3 * (90th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.4 * (90th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	2
75th + percentile of rates for Comparison Geographic Areas during the BY	1.1 * (75th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.2 * (75th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.3 * (75th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.4 * (75th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.5
50th + percentile of rates for Comparison Geographic Areas during the BY	1.1 * (50th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.2 * (50th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.3 * (50th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.4 * (50th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1
30th + percentile of rates for Comparison Geographic Areas during the BY	1.1 * (30th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.2 * (30th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.3 * (30th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.4 * (30th+ Percentile of benchmark rates for Comparison Geographic Areas during the BY)	0.5
<30th percentile of rates for Comparison Geographic Areas during the BY	1.1 * (<30th Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.2 * (<30th Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.3 * (<30th Percentile of benchmark rates for Comparison Geographic Areas during the BY)	1.4 * (<30th Percentile of benchmark rates for Comparison Geographic Areas during the BY)	0

As described in § 512.370(b)(2) of the CY 2022 ESRD PPS final rule, for MY3 through MY10, CMS stratifies achievement benchmarks based on the proportion of beneficiary years attributed to the aggregation group for which attributed beneficiaries are dual eligible (DE) or low income subsidy (LIS) recipients during the MY.¹⁶ An ESRD Beneficiary or Pre-emptive LDT Beneficiary is considered to be dual eligible or a LIS (DE/LIS) recipient for a given month if at any point during the month the beneficiary was DE/LIS recipient based on Medicare administrative data. CMS stratifies the achievement benchmarks into the following two strata:

- (i) Stratum 1: 50 percent or more of attributed beneficiary years during the MY are for beneficiaries who are DE/LIS recipients.
- (ii) Stratum 2: Less than 50 percent of attributed beneficiary years during the MY are for beneficiaries who are DE/LIS recipients.

The DE/LIS Stratum that your aggregation group belongs to for Home Dialysis Achievement Scoring and Transplant Achievement Scoring are displayed on the following tabs of the PPA Report: **“1.MPSPPA_AG”** tab (cell **B9** and **B11** for ESRD facilities and cell **B10** and **B12** for Managing Clinicians), **“2.HDR_AG”** tab (cell **B6** for ESRD facilities and cell **B7** for Managing Clinicians), and **“3.TR_AG”** tab (cell **B5** for ESRD facilities and cell **B6** for Managing Clinicians). CMS publishes the applicable achievement benchmarks on the ETC Model website in advance of each MY.¹⁷ Achievement benchmarks for the MY are also displayed on the **“5.Achievement_Benchmarks”** tab of the PPA Report.

MY Rates

Following the end of the MY, CMS calculates the MY home dialysis rate and transplant rate for each aggregation group of ETC Participants.

The home dialysis rate in the MY for achievement scoring is displayed on the **“2.HDR_AG”** tab of the PPA report (cell **B5** for ESRD facilities and cell **B6** for Managing Clinicians).

The transplant rate in the MY for achievement scoring and its components, including the risk adjusted transplant waitlist rate and LDT rate, are displayed on the **“3.TR_AG”** tab of the PPA report (cells from **B4** to **B18** for ESRD Facilities and cells from **B5** to **B21** for Managing Clinicians).

Achievement Scores

CMS compares ETC Participants' MY rates to the percentile-based benchmarks and assigns points using the scoring methodology displayed in Table 1 to § 512.370(b)(1) of the CY 2022 ESRD PPS final rule and **Exhibit 4** above in the Achievement Benchmarks section. For MY3 and

¹⁶ CY 2022 ESRD PPS final rule newly included the stratification of achievement benchmarks by DE/LIS status for MY3 through MY10.

¹⁷ <https://innovation.cms.gov/innovation-models/esrd-treatment-choices-model>

MY4, an ETC Participant may receive up to 2.0 points when its aggregation group's MY home dialysis rate or transplant rate is at or above 1.1 times the 30th percentile of the corresponding benchmark distribution. If the aggregation group's rate for a given measure is below 1.1 times the 30th percentile, it receives zero points for that rate. For MY5 through MY10, CMS will assign an achievement score to an ETC Participant for the home dialysis rate or the transplant rate only if the ETC Participant's aggregation group has a home dialysis rate or a transplant rate greater than zero for the MY.

The achievement scores for Home Dialysis and Transplant are shown on the **"1.MPSPPA_AG"** tab of the PPA report (cells **B10** and **B12** for ESRD facilities and cells **B11** and **B13** for Managing Clinicians).

IX. Improvement Benchmarking and Scoring

As described in § 512.370(c) (Improvement Scoring) of the Specialty Care Models final rule, CMS assesses ETC Participant's aggregation group's improvement on the home dialysis rate and transplant rate against benchmarks constructed based on the ETC Participant's aggregation group's historical performance on the home dialysis rate and transplant rate during the BY. To determine improvement scores for ETC Participants, CMS calculates the percent improvement from BY to MY at the aggregation group level and then assigns improvement points based on the improvement score sliding scale. In addition, as specified in § 512.370(c)(2) of the CY 2022 ESRD PPS final rule, for MY3 through MY10, CMS assesses ETC Participant improvement on the home dialysis rate and transplant rate for ESRD Beneficiaries and, if applicable, Pre-emptive LDT Beneficiaries, who are DE/LIS recipients to determine whether to add the Health Equity Incentive (HEI) to the ETC Participant's improvement score.¹⁸

Improvement Benchmarks

CMS assesses the home dialysis rate and transplant rate for each ETC Participant in the MY against the BY rates to calculate an improvement score. Improvement in the ETC Model is assessed based on historical rates of the ETC Participant's aggregation group's own home dialysis rate and transplant rate during the BY. Improvement benchmark rates are based on 12 months of data (BY) beginning 18 months before the start of the MY and ending 6 months prior to the MY.

For MY3 through MY10, when calculating improvement benchmarks constructed based on the ETC Participant's aggregation group's historical performance on the home dialysis rate and

¹⁸ CY 2022 ESRD PPS final rule newly included the HEI for MY3 through MY10.

transplant rate during the BY, CMS adds one beneficiary month to the numerator of the home dialysis rate and adds one beneficiary month to the numerator of the transplant rate, such that the BY rates cannot be equal to zero.¹⁹

The home dialysis rate in the BY for improvement benchmarking is on the **“2.HDR_AG”** tab (cell **B4** for ESRD facilities and cell **B5** for Managing Clinicians). The transplant rate in the BY for improvement benchmarking along with its components are on the **“3.TR_AG”** tab of the PPA report (cells from **B19** to **B32** for ESRD facilities and cells from **B22** to **B37** for Managing Clinicians).

MY Rates

The home dialysis rate in the MY for improvement scoring is the same as the MY Home Dialysis Rate for Achievement Scoring, which was described in Section VIII.

The home dialysis rate in the MY for improvement scoring is displayed on the **“2.HDR_AG”** tab of the PPA report (cell **B5** for ESRD facilities and cell **B6** for Managing Clinicians).

The transplant rate in the MY for improvement scoring differs from the transplant rate in the MY for achievement scoring, which is described in Section VIII, in the way the transplant waitlist rate is risk adjusted. The reference population rate in the risk-adjustment formula for improvement scoring equals the observed rate for all ESRD beneficiaries attributed to participating providers, instead of non-participating providers as in the achievement scoring, during the BY.

The transplant rate in the MY for improvement scoring and its components are displayed on the **“3.TR_AG”** tab of the PPA report (cells from **B33** to **B46** for ESRD facilities and cells from **B38** to **B53** for Managing Clinicians).

Percent Improvement

CMS calculates the percent improvement as follows:

$$\text{Percent Improvement} = \frac{(\text{MY Rate} - \text{BY Rate})}{\text{BY Rate}} \times 100$$

The percent improvement for Home Dialysis is displayed on the **“2.HDR_AG”** tab (cell **B7** for ESRD facilities and cell **B8** for Managing Clinicians) and the percent improvement for Transplant is displayed on the **“3.TR_AG”** tab of the PPA report (cell **B47** for ESRD facilities and cell **B54** for Managing Clinicians).

¹⁹ CY 2022 ESRD PPS final rule newly added this condition of adding one beneficiary month to the numerator of the home dialysis rate and transplant rate such that the BY rates cannot be equal to zero.

Health Equity Incentive

The HEI is the additional points that will be added to the ETC Participant's improvement score for MY3 through MY10, if the ETC Participant's aggregation group demonstrated sufficient improvement on the home dialysis rate or transplant rate for attributed beneficiaries who are DE/LIS recipients between the BY and the MY.

As specified in § 512.370(c)(2)(Health Equity Incentive) of the CY 2022 ESRD PPS final rule, CMS calculates the ETC Participant's aggregation group's home dialysis rate and transplant rate as specified in §§ 512.365(b) and 512.365(c), respectively, using only attributed beneficiary years comprised of months during the MY in which ESRD Beneficiaries and, if applicable, Pre-emptive LDT Beneficiaries, are DE/LIS recipients. CMS also calculates the threshold for earning the HEI based on the ETC Participant's aggregation group's historical performance on the home dialysis rate and transplant rate during the BY, using only attributed beneficiary years comprised of months during the BY in which ESRD Beneficiaries and, if applicable, Pre-emptive LDT Beneficiaries, are DE/LIS recipients. An ESRD Beneficiary or Pre-emptive LDT Beneficiary is considered to be DE/LIS recipient for a given month if at any point during the month the beneficiary was DE/LIS recipient. CMS determines whether a beneficiary was DE/LIS recipient based on Medicare administrative data.

- The ETC Participant earns the HEI for the home dialysis rate improvement score if the home dialysis rate for the MY is at least 2.5-percentage points higher than the home dialysis rate for the BY. If the ETC Participant earns the HEI for the home dialysis rate improvement score, CMS adds 0.5 points to the ETC Participant's home dialysis rate improvement score, unless the ETC Participant is ineligible to receive the Home Equity Incentive as specified in § 512.370(c)(2)(iii) of the CY 2022 ESRD PPS final rule.
- The ETC Participant earns the HEI for the transplant rate improvement score if the home dialysis rate for the MY is at least 2.5-percentage points higher than the transplant rate for the BY. If the ETC Participant earns the HEI for the transplant rate improvement score, CMS adds 0.5 points to the ETC Participant's transplant rate improvement score unless the ETC Participant is ineligible to receive the Home Equity Incentive as specified in § 512.370(c)(2)(iii) of the CY 2022 ESRD PPS final rule.
- As specified in § 512.370(c)(2)(iii) of the CY 2022 ESRD PPS final rule, an ETC Participant in an aggregation group with fewer than 11 attributed beneficiary years comprised of months in which ESRD Beneficiaries and, if applicable, Pre-emptive LDT Beneficiaries, are DE/LIS recipients, during either the BY or the MY is ineligible to earn the HEI.

The HEI for home dialysis and the HEI for transplant are displayed on the **"1.MPSPPA_AG"** tab of the PPA report (cells **B14** and **B16** for ESRD facilities and cells **B15** and **B17** for Managing

Clinicians). The components of the HEI for home dialysis including numerators, denominators, rates, and the difference between the BY and MY rates, are displayed on the “**2.HDR_AG**” tab of the PPA report (cells from **B22** to **B28** for ESRD facilities and cells from **B23** to **B29** for Managing Clinicians). The components of the HEI for transplant including numerators, denominators, rates, and the difference between the BY and MY rates, are displayed on the “**3.TR_AG**” tab of the PPA report (cells from **B48** to **B66** for ESRD facilities and cells from **B55** to **B77** for Managing Clinicians).

Improvement Scores

CMS uses the scoring scale in **Exhibit 5** to assign improvement points. Under the improvement score sliding scale, an ETC Participant receives up to 1.5 points based on its aggregation group’s percentage of improvement from its rate in the corresponding BY. For example, if an ETC Participant’s aggregation group achieves a 3% improvement on the home dialysis rate relative to its BY rate, it would receive 0.5 improvement points. An aggregation group with an MY rate less than or equal to the BY rate receives zero points for improvement on that measure.²⁰

Exhibit 5. Improvement Score Scale and Applicable Points

Improvement Score Scale	Points
>10% improvement relative to the BY rate	1.5
>5% improvement relative to the BY rate	1
>0% improvement relative to the BY rate	0.5
≤ the BY rate	0

The improvement scores for Home Dialysis and Transplant are given on the “**1.MPSPPA_AG**” tab of the PPA report (cells **B13** and **B15** for ESRD facilities and cells **B14** and **B16** for Managing Clinicians).

²⁰ The 0.5 additional points an ETC Participant can earn as HEI on its home dialysis rate and transplant rate improvement scores are in addition to the points shown in this exhibit.

X. Modality Performance Score

The Modality Performance Score (MPS) is the numeric performance score calculated for an ESRD facility or Managing Clinician based on their aggregation group's home dialysis rate and transplant rate which is used to determine the PPA. Every member of an aggregation group receives the same MPS.

As described in §512.370(d)(2) of the CY 2022 ESRD PPS final rule, CMS calculates the ETC Participant's MPS as the higher of the ETC Participant's achievement score for the home dialysis rate or the sum of the ETC Participant's improvement score for the home dialysis rate calculated as specified in paragraph (c)(1) of this section and, if applicable, the HEI, calculated as described in paragraph (c)(2)(i) of this section, together with the higher of the ETC Participant's achievement score for the transplant rate or the sum of the ETC Participant's improvement score for the transplant rate calculated as specified in paragraph (c)(1) of this section and, if applicable, the Health Equity Incentive, calculated as described in paragraph (c)(2)(ii) of this section, weighted such that the ETC Participant's score for the home dialysis rate constitutes 2/3 of the MPS and the ETC Participant's score for the transplant rate constitutes 1/3 of the MPS. CMS uses the following formula to calculate the ETC Participant's MPS for MY3 through MY10:

$$MPS = 2 * \left(\frac{\text{The higher of the home dialysis achievement score or (home dialysis improvement score + Health Equity Bonus}^{21})}{\text{Health Equity Bonus}^{21}} \right) + \left(\frac{\text{The higher of the transplant achievement score or (transplant improvement score + Health Equity Bonus}^{22})}{\text{Health Equity Bonus}^{22}} \right)$$

The MPS is shown on the “**1.MPSPPA_AG**” tab (cell **B17** for ESRD facilities and cell **B18** for Managing Clinicians).

²¹ The HEI is applied to the home dialysis improvement score only if earned by the ETC Participant.

²² The HEI is applied to the transplant improvement score only if earned by the ETC Participant.

XI. Performance Payment Adjustment

As described in § 512.375(a) (Facility PPA) of the Specialty Care Models final rule, CMS adjusts the Adjusted ESRD PPS per Treatment Base Rate by the Facility PPA on claim lines with Type of Bill 072X, when the claim is submitted by an ETC Participant that is an ESRD facility and the beneficiary is at least 18 years old before the first day of the month, on claims with claim service dates during the applicable PPA Period as described in §512.355(c) (Measurement Years and Performance Payment Adjustment Periods) of the Specialty Care Models final rule.

As described in § 512.375(b) (Clinician PPA) of the Specialty Care Models final rule, CMS adjusts the amount otherwise paid under Medicare Part B with respect to MCP claims on claim lines with CPT® codes 90957, 90958, 90959, 90960, 90961, 90962, 90965 and 90966 by the Clinician PPA when the claim is submitted by an ETC Participant who is a Managing Clinician and the beneficiary is at least 18 years old before the first day of the month, on claims with claim service dates during the applicable PPA Period as described in § 512.355(c) (Measurement Years and Performance Payment Adjustment Periods) of the Specialty Care Models final rule.

As described in § 512.380 (PPA Amounts and Schedules) of the Specialty Care Models final rule, CMS adjusts the payments described in § 512.375 (Payments Subject to Adjustment) based on the ETC Participant's MPS calculated as described in § 512.370(d) (Modality Performance Score) according to the following amounts and schedules in Table 1 and Table 2 to § 512.380 (PPA Amounts and Schedules) of the Specialty Care Models final rule as shown in Exhibit 6 and 7, respectively. These tables are also displayed on the “**6.PPA_Rubric**” tab of the PPA Report.

Exhibit 6. Facility Performance Payment Adjustment Amounts and Schedule

MPS	Performance Payment Adjustment Period				
	1 and 2	3 and 4	5 and 6	7 and 8	9 and 10
≤ 6	+4.0%	+5.0%	+6.0%	+7.0%	+8.0%
≤ 5	+2.0%	+2.5%	+3.0%	+3.5%	+4.0%
≤ 3.5	0%	0%	0%	0%	0%
≤ 2	-2.5%	-3.0%	-3.5%	-4.5%	-5.0%
≤ .5	-5.0%	-6.0%	-7.0%	-9.0%	-10.0%

Exhibit 7. Clinician Performance Payment Adjustment Amounts and Schedule

MPS	Performance Payment Adjustment Period				
	1 and 2	3 and 4	5 and 6	7 and 8	9 and 10
≤ 6	+4.0%	+5.0%	+6.0%	+7.0%	+8.0%
≤ 5	+2.0%	+2.5%	+3.0%	+3.5%	+4.0%
≤ 3.5	0%	0%	0%	0%	0%
≤ 2	-2.5%	-3.0%	-3.5%	-4.0%	-4.5%
≤ .5	-5.0%	-6.0%	-7.0%	-8.0%	-9.0%

An ESRD facility that is an ETC Participant in an MY will receive a single PPA rate for the corresponding PPA Period.

A Managing Clinician that is an ETC Participant may receive different PPA rates for a PPA Period. This is because PPA is calculated at the billing TIN-level for Managing Clinicians and it is possible for a Managing Clinician (individual NPI) to bill MCP claims through multiple TINs during an MY. A Managing Clinician who billed through multiple TINs in an MY may, therefore, receive separate PPA rates for its various NPI-TIN combinations. If a Managing Clinician has several NPI-TIN combinations in an MY with corresponding PPA rates, CMS will follow the methodology described below to implement the PPA.

This methodology is illustrated with an example where there are three TINs for an NPI:

- TIN1 and TIN2 through which the NPI billed in both the BY and MY and have PPA rates calculated, and
- TIN3 through which the NPI started billing in the PPA Period.

A similar approach will be used if there are more than three TINs associated with one NPI.

If NPI-TIN1 and NPI-TIN2 combinations exist in both the BY and MY, and also exist in the PPA Period, then, during the PPA period, the claims from NPI-TIN1 will be adjusted using the PPA rate of NPI-TIN1 and claims from NPI-TIN2 will be adjusted using the PPA rate of NPI-TIN2. If claims from NPI-TIN3, a combination which was not present during the BY or MY, and, hence, did not have a PPA rate calculated based on its previous performance, appeared in the PPA Period, its payments will be adjusted using the PPA rate for the TIN (TIN1 or TIN2) that had the most attributed beneficiary months in the MY. In the case of a tie in terms of the number of attributed beneficiary months, CMS will use the more favorable PPA rate of the two.

CMS will provide the Managing Clinician with a separate PPA report for each of its NPI-TIN combinations.

The PPA is shown on the “**1.MPSPPA_AG**” tab (cell **B18** for ESRD facilities and cell **B19** for Managing Clinicians).

XII. Missing PPA

An ETC Participant may not receive a PPA in an MY because of two possible reasons, which are displayed on the “**1.MPSPPA_AG**” tab (cell **B19** for ESRD facilities and cell **B20** for Managing Clinicians), if applicable.

1. The aggregation group did not meet the Low Volume Threshold (LVT).
 - a. ESRD Facilities: As described in §512.385(a) (ESRD Facilities) of the Specialty Care Models final rule, CMS excludes an aggregation group (as described in Section V) of Subsidiary ESRD facilities with fewer than 11 attributed ESRD beneficiary years (132 attributed ESRD beneficiary months) during an MY from the applicability of the Facility PPA for the corresponding PPA Period. CMS excludes ESRD facilities that are not Subsidiary ESRD facilities with fewer than 11 attributed ESRD beneficiary years (132 attributed ESRD beneficiary months) during an MY from the applicability of the Facility PPA for the corresponding PPA Period.
 - b. Managing Clinicians: As described in §512.385(b) (Managing Clinicians) of the Specialty Care Models final rule, CMS excludes an aggregation group (as described in in Section V) of Managing Clinicians with fewer than 11 attributed ESRD beneficiary years during an MY from the applicability of the Clinician PPA for the corresponding PPA Period.

The status of the aggregation groups in terms of LVT is shown on the “**1.MPSPPA_AG**” tab (cell **B8** for ESRD facilities and cell **B9** for Managing Clinicians). Even though an aggregation group does not meet the LVT, and therefore is not eligible to receive a PPA, CMS will still calculate and report the home dialysis and transplant performance rates and scores as well as the MPS for that aggregation group.

2. The ETC Participant is not “fully stable”. If an ETC Participant changes its organizational status through closure, or changes parent affiliation, or did not exist in both BY and MY, it is not considered fully stable across BY and MY.
 - a. A fully stable ESRD facility is an ESRD facility that exists in both the BY and the MY and satisfies one of the three below conditions:

- i. The ESRD facility (subsidiary or independent) appears in the same aggregation group in both the BY and the MY.
 - ii. The subsidiary ESRD facility maintains the same affiliation with a chain in both the BY and the MY but moves from one participating HRR in the BY to another participating HRR in the MY. For such ESRD facilities, the BY rate of the old aggregation group is used for the applicable improvement benchmark rate, and the MY rate of the new aggregation group is used for the applicable improvement scoring rate.
 - iii. The independent ESRD facility remains independent in both the BY and the MY but moves from one participating HRR in the BY to another participating HRR in the MY. For such ESRD facilities, the BY rate of the old aggregation group is used for the applicable improvement benchmark rate, and the MY rate of the new aggregation group is used for the applicable improvement scoring rate.
- b. A fully stable Managing Clinician is a Managing Clinician (NPI-TIN) who exists in both the BY and the MY and satisfies one of the three below conditions:
 - i. The Managing Clinician (solo practitioner or group practice) appears in the same aggregation group in both the BY and the MY.
 - ii. The Managing Clinician in a group practice maintains the same affiliation with that group practice (TIN) in both the BY and the MY but moves from one participating HRR in the BY to another participating HRR in the MY. For such Managing Clinicians, the BY rate of the old aggregation group is used for the applicable improvement benchmark rate, and the MY rate of the new aggregation group is used for the applicable improvement scoring rate.
 - iii. The solo practitioner Managing Clinician continues to be a solo practitioner in both the BY and the MY but moves from one participating HRR in the BY to another participating HRR in the MY. For such Managing Clinicians, the BY rate of the old aggregation group is used for the applicable improvement benchmark rate, and the MY rate of the new aggregation group is used for the applicable improvement scoring rate.
- c. Only ESRD facilities and Managing Clinicians that are fully stable will get a PPA. Furthermore, for ETC Participants that are not fully stable, the home dialysis and transplant performance rates and scores, and the MPS will also be missing. The parameters related to stability, including the ESRD facility's and Managing Clinician's HRR number and aggregation group affiliation during BY and MY are

displayed on the “**1.MPSPPA_AG**” tab (cells from **B4** to **B7** for ESRD facilities and cells from **B5** to **B8** for Managing Clinicians). The “**4.AG_Participant_List**” tab indicates which ESRD facilities (**Column D**) or Managing Clinicians (**Column C**) in a Participant’s aggregation group are “fully stable” during the BY and the MY of the associated PPA period.

XIII. Targeted Review

As described in § 512.390(b) (Targeted Review Process) of the Specialty Care Models final rule, an ETC Participant may request a targeted review of the calculation of the MPS. Requests for targeted review are limited to the calculation of the MPS and may not be submitted in regards to: The methodology used to determine the MPS; or the establishment of the home dialysis rate methodology, transplant rate methodology, achievement and improvement benchmarks and benchmarking methodology, or PPA amounts.

CMS will respond to each request for targeted review timely submitted and determine whether a targeted review is warranted. If, upon completion of a targeted review, CMS finds that there was an error in the calculation of the ETC Participant's MPS such that an incorrect PPA has been applied during the PPA period, CMS shall notify the ETC Participant and must resolve any resulting discrepancy in payment that arises from the application of an incorrect PPA in a time and manner determined by CMS. Decisions based on targeted review are final, and there is no further review or appeal.

ETC Participants must send their targeted review request to the ETC help desk: ETC-CMMI@cms.hhs.gov. ETC Participants have 90-days from the day the PPA reports are posted on 4i to contest their scores. CMS will not process requests received after the 90-day window has closed.

- For ESRD Facilities, the following details MUST be included in the targeted review request:
 - “ETC Targeted Review” in the subject line of the help desk ticket/email
 - Legal Business Name of the ESRD facility
 - CCN
 - HRR
 - The PPA Period for which the request is being submitted
 - A complete outline/detail for the targeted review request
 - Ticket Number of the original request if there are any follow-up tickets.

- » Please note – the decision made through the targeted review is final and there will be no re-appeal requests, however, if there are additional questions or follow-up that can be requested through another ticket.
- For Managing Clinicians, the following details MUST be included in the targeted review request:
 - “ETC Targeted Review” in the subject line of the help desk ticket/email
 - Name of the Managing Clinician
 - NPI
 - TIN
 - HRR
 - The PPA Period for which the request is being submitted
 - A complete outline/detail for the targeted review request
 - Ticket Number of the original request if there are any follow-up tickets.
 - » Please note – the decision made through the targeted review is final and there will be no re-appeal requests, however, if there are additional questions or follow-up that can be requested through another ticket.
- Any additional information that the ETC Participant feels is important to both identify the issue and allow CMS to conduct the review appropriately may be included.

Failure to include the above-mentioned details in the help desk tickets can result in an end to the review process as these are minimum required details to appropriately identify the targeted review request. If additional information is requested by CMS then the ETC Participant has 30 days to reply to that request. Failure to respond to the request will result in the termination of the targeted review.

CMS will inform the ETC Participant whether their request was accepted for further review or not within 60 days of receipt of the original appeal request. CMS will provide updates and the progress of the review through the help desk ticket. Please include all inquiries and follow-up within the help desk ticket. Please include the original ticket number if it is closed for any reason for tracking purposes.

After the review has completed, CMS will notify the ETC Participant within 30 days whether there is a change in their score and if this affects any of the claims already processed. CMS will provide updates about the reprocessing of claims through either the help desk ticket or the ETC newsletter. If the review necessitates a change in a participant’s PPA report, CMS will provide access to the PPA report with the updated PPA results through the 4i portal.

XIV. Administrative Review

The CY2024 ESRD PPS final rule amends the Specialty Care Models final rule § 512.390 (Notification, Data Sharing, and Targeted Review) to allow an ETC Participant to seek review by the CMS Administrator or her or his designee of targeted review determinations made by the ETC Model team as follows:

(d) Review of targeted review decisions. The Administrator may review a targeted review request when administrative review is requested by an ETC Participant within 15 calendar days of a targeted review request determination made by CMS.

(1) Administrative review. Within 45 days of the date of the ETC Participant's request for administrative review, the CMS Administrator may act as follows:

- (i) Decline to review a targeted review request determination made by CMS;
- (ii) Render a final decision based on the CMS Administrator's review of the targeted review request determination; or
- (iii) Choose to take no action on the request for administrative review.

(2) Administrative review determinations. The targeted review determination made by the CMS Administrator is final if the CMS Administrator declines an ETC Participant's request for administrative review or if the CMS Administrator does not take any action on the ETC Participant's request for administrative review by the end of the 45-day period described in paragraph (d)(1) of this section.

XV. Appendix

Exhibit 8. Crosswalk between the PPA Report User Guide and PPA Report²³

Information	User Guide Section	Report Tab	Cell for ESRD Facilities	Cell for Managing Clinicians
List of ETC Participants at the end of the MY in the ETC Participant's aggregation group	V. Aggregation Groups	4.AG_Participant_List	-	-
Achievement Benchmarks for the MY	VIII. Achievement Benchmarking and Scoring	5.Achievement_Benchmarks	-	-
DE/LIS Stratum for Home Dialysis Achievement Scoring	VIII. Achievement Benchmarking and Scoring	1.MPSPPA_AG	B9	B10
DE/LIS Stratum for Home Dialysis Achievement Scoring	VIII. Achievement Benchmarking and Scoring	2.HDR_AG	B6	B7
DE/LIS Stratum for Transplant Achievement Scoring	VIII. Achievement Benchmarking and Scoring	1.MPSPPA_AG	B11	B12
DE/LIS Stratum for Transplant Achievement Scoring	VIII. Achievement Benchmarking and Scoring	3.TR_AG	B5	B6
Home Dialysis Rate in the MY for Achievement Scoring	VIII. Achievement Benchmarking and Scoring	2.HDR_AG	B5	B6
Transplant Rate in the MY for Achievement Scoring and its components	VIII. Achievement Benchmarking and Scoring	3.TR_AG	B4-B18	B5-B21
Achievement Scores for Home Dialysis and Transplant	VIII. Achievement Benchmarking and Scoring	1.MPSPPA_AG	B10&B12	B11&B13
Home Dialysis Rate in the BY for Improvement Benchmarking	IX. Improvement Benchmarking and Scoring	2.HDR_AG	B4	B5
Transplant Rate in the BY for Improvement Benchmarking and its components	IX. Improvement Benchmarking and Scoring	3.TR_AG	B19-B32	B22-B37
Home Dialysis Rate in the MY for Improvement Scoring	IX. Improvement Benchmarking and Scoring	2.HDR_AG	B5	B6
Transplant Rate in the MY for Improvement Scoring and its components	IX. Improvement Benchmarking and Scoring	3.TR_AG	B33-B46	B38-B53
Percent Improvement for Home Dialysis	IX. Improvement Benchmarking and Scoring	2.HDR_AG	B7	B8
Percent Improvement for Transplant	IX. Improvement Benchmarking and Scoring	3.TR_AG	B47	B54
Health Equity Incentive for Home Dialysis and Transplant	IX. Improvement Benchmarking and Scoring	1.MPSPPA_AG	B14 & B16	B15 & B17
Components of the Health Equity Incentive for Home Dialysis	IX. Improvement Benchmarking and Scoring	2.HDR_AG	B22-B28	B23-B29
Components of the Health Equity Incentive for Transplant	IX. Improvement Benchmarking and Scoring	3.TR_AG	B48-B66	B55-B77
Improvement Scores for Home Dialysis and Transplant	IX. Improvement Benchmarking and Scoring	1.MPSPPA_AG	B13 & B15	B14 & B16
Modality Performance Score (MPS)	X. Modality Performance Score	1.MPSPPA_AG	B17	B18
PPA Amounts and Schedules	XI. Performance Payment Adjustment	6.PPA_Rubric	-	-
Performance Payment Adjustment (PPA)	XI. Performance Payment Adjustment	1.MPSPPA_AG	B18	B19

²³ The order of the crosswalk is based on the appearance of the information in the PPA Report User Guide.

Information	User Guide Section	Report Tab	Cell for ESRD Facilities	Cell for Managing Clinicians
Reason(s) for Missing PPA	XII. Missing PPA	1.MPSPPA_AG	B19	B20
Low Volume Threshold (LVT) Status	XII. Missing PPA	1.MPSPPA_AG	B8	B9
Parameters related to Stability	XII. Missing PPA	1.MPSPPA_AG	B4-B7	B5-B8
List of “fully stable” participants in an aggregation group during the MY and the BY	XII. Missing PPA	4.AG_Participant_List	Column D	Column C